Jason Firdette, Senior VP of Investor Relations and Corporate Communications, Mersana: Yeah. I’ll take that. So, so this yes. STING agonist, HER2, ADC, that we are in dose escalation with.

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.

MERSANA THRPEUTIC ($MRSN) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$0.11 per share, beating estimates of -$0.16 by $0 ...

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...

On today's call, we have Mersana's Chief Executive Officer ... 2056 is our immunosynthen STING agonist ADC targeting a novel epitope of HER2. Later in 2025, we plan to present initial ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics ...